Liothyronine modified release - Archimedes/T3 Therapeutics
Alternative Names: T3; T3-modified releaseLatest Information Update: 02 Oct 2021
At a glance
- Originator T3 Therapeutics LLC
- Developer Archimedes Pharma; T3 Therapeutics
- Class Amino acids; Small molecules; Thyronines
- Mechanism of Action Thyroid hormone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure; Hypothyroidism
Most Recent Events
- 12 Sep 2011 No development reported - Phase-I for Congestive heart failure in USA (PO)
- 12 Sep 2011 No development reported - Phase-I for Hypothyroidism in USA (PO)
- 06 Jun 2008 Phase-I clinical trials in Congestive heart failure in USA (PO)